What it's for (Indications)
- Loteprednol etabonate ophthalmic suspension is indicated for the treatment of various steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
- These conditions include, but are not limited to, allergic conjunctivitis, anterior uveitis (iritis, cyclitis), ocular inflammation following ocular surgery, and superficial punctate keratitis.
- It is primarily used to reduce inflammation, redness, swelling, and discomfort associated with these conditions, offering targeted relief in the eye.
- The selection of this corticosteroid often depends on the physician's clinical assessment of the inflammatory process and the potential need for a corticosteroid with a favorable safety profile regarding intraocular pressure elevation compared to older, more potent steroids.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of loteprednol etabonate ophthalmic suspension varies depending on the specific condition being treated and its severity. For the treatment of post-operative inflammation following ocular surgery, a typical regimen involves instilling one drop into the conjunctival sac of the affected eye four times daily, starting 24 hours after surgery and continuing for approximately two weeks. For steroid-responsive inflammatory conditions such as allergic conjunctivitis or anterior uveitis, the usual dosage is one drop into the affected eye two to four times daily. Treatment duration should be limited, and patients should be re-evaluated by an ophthalmologist if there is no improvement after a few days, or if the treatment extends beyond two weeks, to monitor for potential adverse effects, including intraocular pressure changes and secondary infections. Adherence to the prescribed dosage and duration is crucial to minimize risks. |
Safety & Warnings
Common Side Effects
- Patients using loteprednol etabonate may experience various side effects, predominantly localized to the eye.
- Common ocular adverse reactions include transient stinging or burning sensation upon instillation, blurred vision, discharge, epiphora (excessive tearing), foreign body sensation, itching, and dry eyes.
- More serious, albeit less common, ocular adverse effects are associated primarily with prolonged use and include elevations in intraocular pressure (IOP) which can lead to glaucoma with potential optic nerve damage, posterior subcapsular cataract formation, and secondary ocular infections, particularly fungal and viral (e.
- g.
- , herpes simplex keratitis).
- Systemic absorption is generally minimal due to its rapid metabolism, thus systemic corticosteroid side effects (such as Cushing's syndrome or adrenal suppression) are exceedingly rare with topical ocular application.
- However, patients should report any unusual or worsening symptoms to their prescribing physician promptly.
Serious Warnings
- Black Box Warning: Loteprednol etabonate does NOT carry a formal Black Box Warning issued by the U.S. Food and Drug Administration (FDA). However, it is crucial for healthcare professionals and patients to be aware of several serious risks associated with the use of ocular corticosteroids, particularly with prolonged or inappropriate administration. These serious warnings include the potential for significant increases in intraocular pressure (IOP) leading to glaucoma with damage to the optic nerve, visual acuity defects, and field defects. Furthermore, the prolonged use of corticosteroids can lead to the formation of posterior subcapsular cataracts. There is also a substantial risk of secondary ocular infections (bacterial, fungal, or viral) due to the immunosuppressive effects of corticosteroids, with fungal infections being particularly insidious and difficult to diagnose. Corticosteroids can mask signs of infection and delay healing of corneal wounds. Patients should be closely monitored by an ophthalmologist for these serious adverse effects, especially if treatment extends beyond 10 days. Misuse or prolonged use without medical supervision can lead to irreversible visual impairment.
- Careful monitoring is essential when prescribing loteprednol etabonate.
- Prolonged use (typically beyond 10 days) of ophthalmic corticosteroids, including loteprednol, may lead to increased intraocular pressure (IOP) in susceptible individuals, potentially resulting in glaucoma with optic nerve damage, visual acuity defects, and field defects.
- Regular intraocular pressure monitoring is therefore recommended for patients on extended therapy.
- Additionally, prolonged corticosteroid use can contribute to the formation of posterior subcapsular cataracts.
- Corticosteroids can mask or exacerbate existing ocular infections, including bacterial, fungal, and viral infections.
- The use of corticosteroids in active herpes simplex keratitis is generally contraindicated and requires extreme caution in patients with a history of the condition.
- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term topical corticosteroid application, and fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use.
- Delay in corneal wound healing may also occur.
- Patients should not wear contact lenses during treatment of active ocular inflammation.
How it Works (Mechanism of Action)
Loteprednol etabonate is a 'site-active' corticosteroid, meaning it is designed to exert its therapeutic anti-inflammatory effects locally within the eye and then rapidly metabolize into inactive forms, thereby minimizing systemic exposure and reducing the risk of systemic corticosteroid side effects. As a corticosteroid, it acts by inhibiting the inflammatory response to a variety of inciting agents. Specifically, it induces the production of lipocortins, which are phospholipase A2 inhibitory proteins. By inhibiting phospholipase A2, loteprednol etabonate reduces the release of arachidonic acid from cell membrane phospholipids, consequently preventing the synthesis of potent inflammatory mediators such as prostaglandins and leukotrienes. This interruption of the inflammatory cascade helps to alleviate symptoms such as swelling, redness, and pain associated with ocular inflammation. Its ester structure allows for effective penetration into ocular tissues while promoting rapid inactivation upon systemic absorption, contributing to its favorable safety profile.
Commercial Brands (Alternatives)
No other brands found for this formula.